Oxford Biomedica (OXB): FY26 guidance trend

This situation live

£622m · 514.0p · +10% since the first step

Upgrade / downgrade cycle

FY26 guidance trend

Guidance at lower level, reiterated at H1

Next: H2-weighted delivery against £180–200m revenue guidance

Every step · 1

22 Sep 2026 Guidance at lower level, reiterated at H1 – Guidance reiterated: FY 2026 constant currency revenue expected to be £180–200 million; FY 2026 EBITDA margin expected to be mid-single-digit % excluding... ↗

What is happening

Oxford Biomedica: FY26 guidance trend – Guidance at lower level, reiterated at H1. ['Guidance at lower level, reiterated at H1']

In short: In March 2026 OXB guided FY26 revenue of £220–240m and a c.10% EBITDA margin. The 22 Sep 2026 H1 results reiterate guidance given after the August trading update: £180–200m revenue and a mid-single-digit margin ex one-offs (low-single-digit reported). About £168m of FY26 revenue is covered by contracted orders as at September 2026.
Announced: 22 Sep 2026 · Guidance at lower level, reiterated at H1
FY26 revenue: £180–200m constant currency (was £220–240m in March 2026)
FY26 EBITDA margin: Mid-single-digit % ex one-offs; low-single-digit % reported (was c.10%)
FY27 growth: Revenue growth of 25-30% year-on-year expected
Order cover: c.£168m of forecast FY26 revenue under contracted client orders (September 2026)

H2-weighted delivery against £180–200m revenue guidance.

From the company's own announcements. Not investment advice.

Briefing Pro

What it does, how it got here, what management promised and delivered – written from its own announcements.

Also at Oxford Biomedica 1 open